733
edits
No edit summary |
No edit summary |
||
Line 12: | Line 12: | ||
* CPVT with previous cardiac arrest. IC<cite>ESCSCD</cite> | * CPVT with previous cardiac arrest. IC<cite>ESCSCD</cite> | ||
* An ICD is recommended in a patient with heart failure with a ventricular arrhythmia causing haemodynamic instability. LE>1y. IA <cite>ESCHF</cite> | * An ICD is recommended in a patient with heart failure with a ventricular arrhythmia causing haemodynamic instability. LE>1y. IA <cite>ESCHF</cite> | ||
* CRTD is recommended in patients with sinus rhythm, LBBB, QRS > 130ms, EF<30%, NYHA II. IA <cite>ESCHF</cite> | * CRTD is recommended in patients with sinus rhythm, LBBB, QRS > 130ms, EF<30%, NYHA II. IA <cite>ESCHF</cite><cite>ESCfocusedup</cite> | ||
* CRTD is recommended in patients with sinus rhythm, LBBB, QRS > 120ms, EF<35%, NYHA III-IV. IA <cite>ESCHF</cite> | * CRTD is recommended in patients with sinus rhythm, LBBB, QRS > 120ms, EF<35%, NYHA III-IV. IA <cite>ESCHF</cite>ESCfocusedup</cite> | ||
* CRT in patient with an other Class I pacemaker indication who is in NYHA III/IV, LVEF ≤35%, QRS ≥120 ms. IB<cite>ESCsyncope</cite> | |||
* Documented VT and structural heart disease. IB <cite>ESCsyncope</cite> | * Documented VT and structural heart disease. IB <cite>ESCsyncope</cite> | ||
* When monomorphic VT is induced at EP study in patients with previous myocardial infarction. IB <cite>ESCsyncope</cite> | * When monomorphic VT is induced at EP study in patients with previous myocardial infarction. IB <cite>ESCsyncope</cite> | ||
Line 30: | Line 31: | ||
* Brugada syndrome with documented VT that has not resulted in cardiac arrest. <cite>ESCSCD</cite> | * Brugada syndrome with documented VT that has not resulted in cardiac arrest. <cite>ESCSCD</cite> | ||
* A CRTD should be considered in a patient with non-LBBB, QRS > 150ms, EF<35%, NYHA III-IV . IIaA<cite>ESCHF</cite> | * A CRTD should be considered in a patient with non-LBBB, QRS > 150ms, EF<35%, NYHA III-IV . IIaA<cite>ESCHF</cite> | ||
* A CRTD should be considered in a patient with non-LBBB, QRS > 150ms, EF<30%, NYHA II . IIaA<cite>ESCHF</cite> | * A CRTD should be considered in a patient with non-LBBB, QRS > 150ms, EF<30%, NYHA II . IIaA<cite>ESCHF</cite><cite>ESCfocusedup</cite><cite>ESCfocusedup</cite> | ||
* A CRTD/CRTP may be considered to reduce the risk of HF worsening in a patient with atrial fibrillation who is pacemaker dependant, after AV nodal ablation QRS > | * A CRTD/CRTP may be considered to reduce the risk of HF worsening in a patient with atrial fibrillation who is pacemaker dependant, after AV nodal ablation QRS > 130ms, EF<35%, NYHA III-IV . IIaA<cite>ESCHF</cite><cite>ESCfocusedup</cite> | ||
* CRT may be considered to reduce the risk of HF worsening in a patient with atrial fibrillation who requires pacing because of intrinsically slow ventricular rate with QRS > 130ms, EF<35%, NYHA III-IV . IIaC<cite>ESCHF</cite><cite>ESCfocusedup</cite> | |||
* In patients with documented VT with inherited cardiomyopathies or channelopathies. IIaB. <cite>ESCsyncope</cite> | * In patients with documented VT with inherited cardiomyopathies or channelopathies. IIaB. <cite>ESCsyncope</cite> | ||
* CRT in patient with an other Class I pacemaker indication who is in NYHA III/IV, LVEF ≤35%, QRS <120 ms. IIaC<cite>ESCsyncope</cite> | |||
==Class IIb (may be considered)== | ==Class IIb (may be considered)== | ||
* nonischemic DCM, LVEF < 30-35%, NYHA I. optimal medical therapy, LE>1y. IIbC<cite>ESCSCD</cite> | * nonischemic DCM, LVEF < 30-35%, NYHA I. optimal medical therapy, LE>1y. IIbC<cite>ESCSCD</cite> | ||
* CRT may be considered to reduce the risk of HF worsening in a patient with atrial fibrillation who requires pacing because of a rate of < 60 bpm in rest and < 90 bpm on exercise with QRS > 120ms, EF<35%, NYHA III-IV . IIbC<cite>ESCHF</cite> | * CRT may be considered to reduce the risk of HF worsening in a patient with atrial fibrillation who requires pacing because of a rate of < 60 bpm in rest and < 90 bpm on exercise with QRS > 120ms, EF<35%, NYHA III-IV . IIbC<cite>ESCHF</cite> | ||
* CRT should be considered in those patient with atrial fibrillation in NYHA functional class II with an EF ≤35%, irrespective of QRS duration, to reduce the risk of worsening of HF. IIbC<cite>ESCHF</cite> | * CRT should be considered in those patient with atrial fibrillation in NYHA functional class II with an EF ≤35%, irrespective of QRS duration, to reduce the risk of worsening of HF. IIbC<cite>ESCHF</cite> | ||
* CRT in patient with an other Class I pacemaker indication who is in NYHA II, LVEF ≤35%, QRS <120 ms. IIbC<cite>ESCsyncope</cite> | |||
==Class III (not recommended)== | ==Class III (not recommended)== | ||
* ICD implantation is not recommended during the acute phase of myocarditis<cite>ESCSCD</cite> | * ICD implantation is not recommended during the acute phase of myocarditis<cite>ESCSCD</cite> | ||
Line 47: | Line 51: | ||
#ESCHF pmid=22828712 | #ESCHF pmid=22828712 | ||
#ESCsyncope pmid=19713422 | #ESCsyncope pmid=19713422 | ||
#ESCfocusedup pmid=20801924 | |||
</biblio> | </biblio> |